A Randomized, Double-Blind, Placebo- and Active Controlled Study to Evaluate the Safety and Efficacy of GRT6005 in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Phase of Trial: Phase II
Latest Information Update: 24 Feb 2019
At a glance
- Drugs Cebranopadol (Primary) ; Oxycodone
- Indications Osteoarthritis; Pain
- Focus Therapeutic Use
- Sponsors Forest Laboratories
- 03 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2013 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 30 Sep 2013 Planned End Date changed from 1 Aug 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.